Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
-
- Arun K. Ghosh
- Department of Chemistry Purdue University West Lafayette IN 47907 USA
-
- Margherita Brindisi
- Department of Chemistry Purdue University West Lafayette IN 47907 USA
-
- Dana Shahabi
- Department of Chemistry Purdue University West Lafayette IN 47907 USA
-
- Mackenzie E. Chapman
- Department of Biochemistry Purdue University West Lafayette IN 47907 USA
-
- Andrew D. Mesecar
- Department of Chemistry Purdue University West Lafayette IN 47907 USA
書誌事項
- 公開日
- 2020-05-07
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/cmdc.202000223
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>The COVID‐19 pandemic caused by SARS‐CoV‐2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID‐19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell‐surface receptors, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA‐dependent RNA polymerase for RNA replication. There has been a lot of ground work for drug discovery and development against these targets. Also, high‐throughput screening efforts have led to the identification of diverse lead structures, including natural product‐derived molecules. This review highlights past and present drug discovery and medicinal‐chemistry approaches against SARS‐CoV, MERS‐CoV and COVID‐19 targets. The review hopes to stimulate further research and will be a useful guide to the development of effective therapies against COVID‐19 and other pathogenic coronaviruses.</jats:p>
収録刊行物
-
- ChemMedChem
-
ChemMedChem 15 (11), 907-932, 2020-05-07
Wiley